Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.

Bausch + Lomb Expands Portfolio Offering with the Acquisition of Acrivet, the Veterinary Division of S&V Technologies GmbH

Transaction Enhances and Broadens Bausch + Lomb’s Surgical Portfolio of Products in the Animal Healthcare Industry



BRIDGEWATER, NJ — Bausch + Lomb, a leading global eye health company, today announces it has agreed to acquire Acrivet, the veterinary division of S&V Technologies GmbH. The addition of Acrivet expands Bausch + Lomb’s surgical product portfolio and pipeline into the animal healthcare market, increasing the company’s reach and creating opportunity for future growth.


“The addition of the strong and diverse Acrivet® veterinary ophthalmic portfolio is an excellent strategic fit with Bausch + Lomb's current business,” said Ari Kellen, M.D., head of U.S. Eye Health, Bausch + Lomb. “This acquisition demonstrates our commitment and passion to provide new technologies for serving the needs of the animal healthcare industry.”  


Through the transaction, Bausch + Lomb will acquire the Acrivet ophthalmology assets, including intraocular lenses, bandage contact lenses and hyaluronate eye gel.   Bausch + Lomb will work to ensure regulatory approvals are sought as appropriate.


Bausch + Lomb’s acquisition of Acrivet will broaden the company’s marketed products and capabilities within its surgical division. The synergies between Bausch + Lomb’s surgical portfolio and the Acrivet veterinary ophthalmic product offerings are expected to drive a strong presence in the growing animal healthcare market. The combined business will also benefit from access to a strong product portfolio.

“Acrivet already has a strong leadership position in the animal healthcare market, and with our combined resources we look forward to providing a more diverse offering of products and solutions to our customers in the veterinary industry,” said Kellen.

The transaction, which has been approved by the boards of directors from Valeant Pharmaceuticals, Inc., and S&V Technologies GmbH, is expected to close in early May 2015.

About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing, and restoring people’s eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. We develop, manufacture and market one of the most comprehensive product portfolios in our industry, which are available in more than 100 countries. 

© 2015 Bausch & Lomb Incorporated

News Media Contacts:

Kristy Marks
Public Relations Product Manager, Bausch + Lomb

(585) 338-8095 or


Tad Heitmann

BioComm Network on behalf of Bausch + Lomb

(714) 273-2937 or




Actions: E-mail | Permalink |